Breaking News! Major Milestone for BriaCell’s Cellular Cancer Vaccines

Breaking News Update + Important Technical Update Breaking News Hits The Wire (NASDAQ: BCTX) Major Milestone for BriaCell’s off-the-shelf personalized Cellular Cancer Vaccines Hi "FDR" Member, I have two very important topics to discuss regarding your "Focus" stock (NASDAQ: BCTX). The stock is quickly trending up right now on huge early morning volume! You need to pay close attention to this stock or you could potentially miss out on another incredible winner. 1.) The 100-Day average volume is 97,522 (BCTX has traded 98k in 1hr) [See here]( 2.) BCTX released Block Buster news this morning. See below Between the stock surging in volume, mixed with breaking news, (BCTX) could be one of my biggest breakout stocks of 2024! Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing - Figure 2 shows that Bria-Pros+ cells can stimulate immune cells to kill prostate cancer cells. - Bria-Pros+ is based on BriaCell’s next generation personalized immunotherapy platform. - Bria-Pros+ is capable of activating multiple types of immune cells, including helper T cells, cytotoxic (killer) T cells and natural killer cells. - Initiation of GMP manufacturing represents a major milestone for BriaCell’s off-the-shelf personalized cellular cancer vaccines HILADELPHIA and VANCOUVER, British Columbia, Feb. 06, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce the initiation of Good Manufacturing Practice (GMP) manufacturing of its lead candidate for treating prostate cancer, Bria-Pros+. GMP manufacturing of Bria-Pros+ will provide clinical supplies for planned clinical trial use. “Building upon the compelling pre-clinical proof-of-concept data presented at the Society for the Immunotherapy of Cancer (SITC) meeting in 2023, BriaCell’s proprietary platform technology holds significant potential to benefit patients across a spectrum of cancers. We are enthusiastic about commencing GMP manufacturing for our prostate cancer clinical candidate, continuing our efforts at transforming targeted cancer therapy via the introduction of potent personalized cellular cancer vaccines,” stated Dr. William V. Williams, BriaCell’s President and CEO. “The successful development of this first candidate showcases our capacity to create novel cancer immunotherapies and advance them towards clinical application. We eagerly anticipate completing Investigational New Drug (IND)-enabling studies during 2024 with Bria-Pros+.” Recently presented at SITC 2023, the pre-clinical proof-of-concept data demonstrated both feasibility and efficacy of BriaCell’s platform of cellular cancer vaccines overall, with specific emphasis on Bria-Pros+. BriaCell genetically engineers cancer cell lines to produce cytokines and co-stimulatory factors that significantly increase immune stimulation compared to the unmodified (parent) cancer cell lines. These cell lines also express patient-specific Human leukocyte antigens (HLA) alleles and potentially provide personalized off the shelf treatment. In the realm of cancer immunotherapy, the objective is to restore the body's natural anti-tumor immunity. Despite notable progress, current approaches often fall short of achieving curative outcomes, primarily because they target specific immune processes, resulting in only partial restoration of the body's inherent anti-cancer immunity. An optimal cancer immunotherapy should initiate or reinstate a persistent anti-tumor immune response via both complementary and diverse mechanisms resulting in a self-sustaining cycle of cancer immunity by both the innate and adaptive immune responses. The data highlighted at the SITC meeting demonstrated that Bria-Pros+ could effectively activate the natural immune response against tumor cells by both expressing cancer antigens, and by modulating the activity of innate and adaptive immune cells. These include helper T cells (CD4+), cytotoxic (killer) T cells (CD8+), and natural killer cells (both Classical NK cells and NKT cells). Data previously presented at the SITC meeting is reproduced here in a different format. Figure 1 shows that Bria-Pros+ activates a range of immune cells in a modified mixed lymphocyte reaction. After 48 hours of co-culture, immune cells were analyzed. CD4+ & CD8+ T cells, NK-T and Classical NK cells were activated as shown here as the % increase in activated cells following Bria-Pros+ stimulation compared with parent cell stimulation. Figure 2 shows that Bria-Pros+ cells can stimulate immune cells to kill prostate cancer cells. Engineered to express co-stimulatory and immuno-modulatory cytokines, Bria-Pros+ cells enhance the ability of immune cells to kill tumor cells. In summary, our data suggests significantly stronger anti-tumor activity for Bria-Pros+ vs that of the parent cells, making it an ideal lead clinical candidate for our upcoming clinical studies in prostate cancer. According to 2024 [Cancer Facts & Figures]( , prostate cancer is projected to be the most common cancer among men in 2024. With 299,010 new cases estimated to be diagnosed in 2024 and 35,250 projected deaths from prostate cancer in 2024, prostate cancer is expected to be the second leading cause of cancer death among men in 2024. Current treatments for metastatic prostate cancer include immunotherapy, hormone therapy, chemotherapy and targeted treatments. Novel approaches are needed for advanced prostate cancer. ------------------------------------------------------------------------------------------------------- Investing.com Technical Opinion Rating Just Triggered BCTX a Bullish STRONG BUY Rating BriaCell Therapeutics Corp. (NASDAQ: BCTX) just triggered the following Technical Indicators signaling a "Bullish Strong Buy Rating" based on Investing.com technical analysis, which could be signaling a breakout. Today is a critical day for you to pay close attention. I’ve been searching for a low float explosive biotech situation with massive upside that has several Wall Street analysts that are bullish and has incredible upside potential. BriaCell Therapeutics (NASDAQ: BCTX) is priced just under $4/share and has a staggering $18/share analyst target price by H.C. Wainwright. [See here]( Bullish Catalyst - H.C. Wainwright Initiated Coverage BriaCell Therapeutics (NASDAQ: BCTX) with Buy rating and $18 Price Target ([Representing +358% in Upside Potential]( Initiating with Buy Rating and $18 PT According to H.C. Wainwright & Co. Analyst Emily Bodnar, BCTX has +358% upside potential based on the analysts’ price target from Monday's close at $3.93. Briacell Therapeutics (NASDAQ: BCTX) is a biotechnology company that focuses on developing innovative cancer immunotherapies. According to H.C. Wainwright & Co. Analyst Emily Bodnar and recent blockbuster news BCTX showed promising signs reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients. BriaCell Therapeutics Corp. (NASDAQ: BCTX) lead targeted cell therapy Bria-IMT, when combined with the PD-1 inhibitor retifanlimab, achieved an [exceptional 71% intracranial objective response rate]( treating brain metastases in advanced breast cancer patients, according to H.C. Wainwright analyst Emily Bodnar in a December 28 research report. Of seven heavily pretreated patients with difficult-to-reach central nervous system lesions enrolled in the ongoing Phase 2 trial, five demonstrated either a partial or complete response. Bodnar believes this indicates Bria-IMT may effectively cross the blood-brain barrier, allowing unique antitumor activity against these metastatic tumors compared to existing standard-of-care therapies. CNS metastases occur in 10-15% of breast cancer patients overall, reaching as high as 25-50% in patients with aggressive HER2-positive or triple-negative disease subtypes. However, Bodnar highlights current targeted treatments like monoclonal antibodies or ADCs rarely exceed a 50% intracranial response rate based on historical data. "We believe an iORR of 71% is differentiated compared to SOC therapies available for breast cancer," Bodnar concludes. Bullish Catalyst – Strong Buy Rating and Price Forecast BCTX is currently trading at approx. $3.93/share and has multiple Bullish Strong BUY Ratings. Stockanalysis reports a Bullish Strong BUY with forecast of an average price target of $18.00. Now Turn Your Complete Attention to BriaCell Therapeutics (NASDAQ: BCTX) Our New Nasdaq Biotech Breakout Alert BriaCell Therapeutics (NASDAQ: BCTX) is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care with near-term catalysts, small float, potential chart breakout, coming off of great news and recent analysts coverage indicating +358% in upside potential. BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset - In the subset of Antibody-Drug Conjugate (ADC) refractory patients, Overall Survival (OS) data of BriaCell’s combination regimen exceeded that of similar studies* - - Progression Free Survival (PFS) was similar or better than last regimen in 40% of the patients highlighting clinical efficacy - - Disease control rate of 40% was observed in evaluable patients further indicating clinical benefit PHILADELPHIA and VANCOUVER, British Columbia, Dec. 20, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to report unprecedented preliminary survival and clinical benefit data in a new subset of advanced breast cancer patients treated with BriaCell’s Bria-IMT™ regimen: patients that have developed resistance to (and failed to respond to) Antibody-Drug Conjugates (“ADC”, “ADCs”). ADCs have significantly advanced cancer therapy in the past few years; however many patients experience serious side effects and others develop resistance to ADCs; therefore, their medical needs remain unmet. “We are excited with our findings of unprecedented survival and clinical benefit in very difficult-to-treat patients who failed ADCs and view our findings as a significant clinical breakthrough in the field of cancer therapy. This is highly encouraging given our ongoing pivotal study is investigating the effects of Bria-IMT™ regimen in advanced breast cancer with overall survival as its primary endpoint,” stated Dr. William V. Williams, BriaCell’s President and CEO. “Armed with our novel immunotherapy, we are hoping to make a meaningful contribution to the lives of patients who have failed ADCs across all breast cancer types.” If you haven't taken a look at this stock yet, this is your chance! Today is a critical day for you to pay close attention to BCTX. To Your Trading Success, Michael Reece Editor, Financial Driven Research © 2023 Financial Driven Research, All Rights Reserved. Financial Driven Research (“FDR” or “Company”) is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or inves∙tment for any specific individual. FDR full disclosure is to be read and fully understood before using FDR website or joining FDR email or sms list. By viewing FDR website and/or reading FDR email or sms list you are agreeing to FDR full disclosure This publication may contain information regarding inves∙tment ideas and third-party ratings regarding specific securities. We hold n∙o inves∙tment licenses and are thus neither licensed nor qualified to provide inves∙tment adv∙ice. FDR nor its principals are not FINRA-registered broker-dealers or inves∙tment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from FDR to buy or sell any security. Always be extremely careful and consult a licensed inves∙tment professional before making any inves∙tment decision as inves∙ting in securities carries a high degree of risk; you may likely lose some or all of the inves∙tment. This communication is a sponsored advertisement. FDR and/or its subsidiaries and/or affiliates has been compensated $20,000 USD to disseminate this communication. Please note we do not hold positions in stocks we profile. We do not trade in any of our sponsored advertisements, or non-sponsored profiles. We do not accept stock as a form of payment for our sponsored advertisements. Please review the full disc∙laimer at [Disc∙laimer and Disclosure Policy]( for important information regarding this sponsored advertisement. © 2023 FDR. All rights reserved., 1014 W 36th St, Baltimore, MD 21211, United States You may [unsubscribe]( or [change your contact details]( at any time. Powered by:[GetResponse](